Mabwell, a Model Case of China’s Booming Biopharma Start-ups
2021) and 2nd in the list of the Top 20 Venture Raises of 2020 in ex-US regions, as listed in LavoieHealthScience (released in Oct. 2020).
- 2021) and 2nd in the list of the Top 20 Venture Raises of 2020 in ex-US regions, as listed in LavoieHealthScience (released in Oct. 2020).
- Founded in 2017, Mabwell focuses on the discovery, development, manufacture, and commercialization of innovative biologics and has set-up 9 subsidiaries to accelerate the industrialization process.
- With this trend, it is easily foreseeable that Chinese biopharma companies will be even more competitive in the global market in the next decade.
- ATLATL is innovations spear thrower to facilitate innovators growth and enhance their ability to reach milestones more quickly than ever.